Apr 25

Access Pharmaceuticals to present two oncology posters in CPR Conference ACCESS PHARMACEUTICALS.

, a biopharmaceutical firm leveraging its proprietary drug-delivery platforms to develop treatments in regions of oncology, cancer supportive diabetes and treatment, announced that two oncology posters are getting shown this week at the Improvements in Cancer Prevention and Research Conference at the Austin Convention Center in Austin, TX. Related StoriesLilly, ImaginAb partner to study potential novel T-cell-based immuno-oncology therapiesNew guidance statement on palliative care to be provided at 2015 Palliative Care in Oncology SymposiumResearchers recognize new focus on for novel immune-oncology treatments’We are very happy to be one of them year’s Innovations in Cancers Prevention and Research Meeting as the team’s study in both programs support a substantial opportunity in treating numerous cancers,’ stated David Nowotnik, Senior VP of Research and Development, Access Pharmaceuticals, Inc.’ The meeting is organized by the Tumor Prevention and Study Institute of Texas .The rate of advancement of BMS-PCSK9Rx exemplifies the efficiency of our technology and our capability to quickly advance from the discovery of a gene to a medication in the clinic,’ stated Stanley T. Crooke, M.D., Ph.D., Chief and Chairman Executive Officer of Isis. ‘Targeting PCSK9 gives a unique approach to lowering LDL cholesterol, which is a essential component in managing and preventing cardiovascular disease. We continue to progress and mature the breadth and depth of our pipeline and the therapeutic opportunities that people can take benefit of with this technology.’ Related StoriesStopping cholesterol medicines before surgery may boost risk of death during recoveryPresence of tophi in people with gout can increase risk of developing cardiovascular diseaseFour microRNAs may actually play critical roles in controlling cholesterol, triglyceride metabolismBMS-PCSK9Rx can be an antisense drug that targets proprotein convertase subtilisin kexin 9, or PCSK9.